Drug Delivery Research Leads to Non-invasive Treatments for Major Diseases
An upcoming conference on Drug Delivery Technology will bring together scientists to discuss research aimed at creating safe and non-invasive treatments for cancer, diabetes, asthma, Alzheimer’s, cardiovascular disease and a host of other conditions.
Monrovia, CA, November 06, 2006 --(PR.com)-- Being diagnosed with diabetes traditionally leads to insulin routines of up 4 injections per day. And cancer detection can mean enduring invasive treatments such as chemotherapy and radiation. But recent advancements in drug delivery technologies are helping to treat these diseases without destroying the patient's quality of life.
An upcoming conference on Drug Delivery Technology will bring together scientists to discuss research aimed at creating safe and non-invasive treatments for cancer, diabetes, asthma, Alzheimer’s, cardiovascular disease and a host of other conditions.
Presenters will examine Intracellular and Gene Drug Delivery, the Delivery of Biologicals, the Pharmacology of Drug Delivery and Recent Clinical Activities. Peter Hoffman, Vice President of New Technology Development for Genzyme Corporation will deliver the keynote address entitled, “American Revolution in CNS Therapy: CNS Drug Delivery”. Hoffman will be joined at this conference by presenters from Bristol-Myers Squibb, Novartis Vaccines, 3M HealthCare Ltd, Genzyme, Merck, Serono and other leading research organizations.
Drug Delivery Technology is a part of the 2nd Modern Drug Discovery & Development Summit (M3D 2006). The Summit will take place December 4-6, 2006 at the Pennsylvania Convention Center. Over 250 speakers will participate in 11 concurrent conferences. For more information, visit www.gtcbio.com
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
For more information contact Christy Bowman at GTCbio. Phone: (626) 256-6405 x101, Fax: (626) 256-6460, Email: Christy.bowman@gtcbio.com
###
An upcoming conference on Drug Delivery Technology will bring together scientists to discuss research aimed at creating safe and non-invasive treatments for cancer, diabetes, asthma, Alzheimer’s, cardiovascular disease and a host of other conditions.
Presenters will examine Intracellular and Gene Drug Delivery, the Delivery of Biologicals, the Pharmacology of Drug Delivery and Recent Clinical Activities. Peter Hoffman, Vice President of New Technology Development for Genzyme Corporation will deliver the keynote address entitled, “American Revolution in CNS Therapy: CNS Drug Delivery”. Hoffman will be joined at this conference by presenters from Bristol-Myers Squibb, Novartis Vaccines, 3M HealthCare Ltd, Genzyme, Merck, Serono and other leading research organizations.
Drug Delivery Technology is a part of the 2nd Modern Drug Discovery & Development Summit (M3D 2006). The Summit will take place December 4-6, 2006 at the Pennsylvania Convention Center. Over 250 speakers will participate in 11 concurrent conferences. For more information, visit www.gtcbio.com
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
For more information contact Christy Bowman at GTCbio. Phone: (626) 256-6405 x101, Fax: (626) 256-6460, Email: Christy.bowman@gtcbio.com
###
Contact
GTCbio
Christy Bowman
626-256-6405
www.gtcbio.com
Christy Bowman
626-256-6405
www.gtcbio.com
Contact
Categories